Behçet’s disease: Recent advances in early diagnosis and effective treatment
| Autor: | Phaedon G. Kaklamanis, Kenneth T. Calamia |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
International Cooperation Disease Behcet's disease medicine.disease_cause law.invention Pathogenesis Pharmacotherapy Rheumatology Randomized controlled trial law Internal medicine Azathioprine medicine Humans Psychiatry Intensive care medicine Glucocorticoids Societies Medical Randomized Controlled Trials as Topic Tumor Necrosis Factor-alpha business.industry Behcet Syndrome Antibodies Monoclonal Immune dysregulation medicine.disease Infliximab Early Diagnosis Practice Guidelines as Topic Drug Therapy Combination business Immunosuppressive Agents medicine.drug |
| Zdroj: | Current Rheumatology Reports. 10:349-355 |
| ISSN: | 1534-6307 1523-3774 |
| DOI: | 10.1007/s11926-008-0057-y |
| Popis: | Behçet's disease (BD) is a chronic, multisystem, inflammatory disorder that is classified among the systemic vasculitidies. Its cause has yet to be determined, but genetic and environmental factors and immune dysregulation are thought to play a role in its pathogenesis. The diagnosis of the disease and recognition and separation from disorders that may mimic BD may be difficult, especially in areas where the disease is uncommon. Certainty as to the best treatments for the various manifestations of BD is often unclear due to limited randomized controlled trials. However, existing consensus statements and expert opinions should help to guide therapy. This review examines important recent contributions to help the clinician more readily recognize patients with the disease and institute appropriate care. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink